High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia.
Cunte ChenChi Leong ChioHui ZengYangqiu LiPublished in: Hematology (Amsterdam, Netherlands) (2021)
The prognostic value of CD56 expression in IR-AML may need to be comprehensively evaluated based on different detection methods, age stratification, countries, treatment options, and other factors. If confirmed, CD56 may be a biomarker for further risk stratification for IR-AML patients.
Keyphrases
- acute myeloid leukemia
- poor prognosis
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- ejection fraction
- nk cells
- chronic kidney disease
- binding protein
- prognostic factors
- peritoneal dialysis
- long non coding rna
- patient reported outcomes
- free survival
- sensitive detection
- label free